Gland Pharma
1,878.00
+44.40(+2.42%)
Market Cap₹30,209.70 Cr
PE Ratio44.26
IndustryHealthcare
Company Performance:
1D+2.42%
1M+16.52%
6M+3.75%
1Y+3.29%
5Y+3.21%
View Company Insightsright
More news about Gland Pharma
04Jun 25
Gland Pharma Secures Approval for Angiotensin II Acetate Injection
Gland Pharma has received approval for its Angiotensin II Acetate Injection, a medication used in treating cardiovascular conditions in critical care settings. The product has reported US sales of approximately USD 58.00 million, indicating a significant market opportunity. This approval is expected to strengthen Gland Pharma's position in the pharmaceutical market, particularly in the United States, and potentially enhance its competitive edge in the specialty pharmaceutical segment.
21May 25
Gland Pharma's Q4 Results Show Core Weakness, Cenexi Challenges
Gland Pharma's Q4 net profit decreased 2.60% year-over-year to ₹1.87 billion, while revenue fell 7.29% to ₹14.25 billion. The company recommended a final dividend of ₹18 per equity share. Despite current challenges, including increased competition and Cenexi-related issues, the company projects a 20% earnings CAGR over FY25-27, driven by new product launches and improving Cenexi performance.
20May 25
Gland Pharma: Q4 Profit and Revenue Decline, Misses Estimates
Gland Pharma's Q4 results show a 3.10% decrease in net profit to ₹186.50 crore and a 7.30% decline in revenue to ₹1,424.90 crore year-over-year. Despite these declines, the company improved its EBITDA margin to 24.40%. The company launched four new molecules, filed five ANDAs, and received seven regulatory approvals. The board proposed a final dividend of ₹18.00 per equity share. Cenexi, its European subsidiary, showed 8.00% year-over-year revenue growth.
19May 25
Gland Pharma Anticipates Stable Q4 Performance with Marginal Revenue Growth
Gland Pharma is expected to report a stable Q4 FY performance with 0.90% YoY revenue growth to Rs 1,551.73 crore. EBITDA is projected to increase by 5.54% to Rs 376.14 crore, indicating potential margin expansion. Key drivers include US business momentum, new product launches, and Cenexi recovery. Investors will focus on updates regarding China expansion and the complex product pipeline.
30Apr 25
Gland Pharma Secures USFDA Approval for Glaucoma Treatment, Gains Exclusivity
Gland Pharma has received USFDA approval for its ANDA for latanoprostene bunod ophthalmic solution, 0.024%, bioequivalent to Bausch and Lomb's VYZULTA. The drug is used to reduce intraocular pressure in glaucoma or ocular hypertension patients. As the first-to-file applicant, Gland Pharma has secured 180 days of generic drug exclusivity. The product's US sales were $171.00 million for the 12 months ending February 2025.
30Apr 25
Gland Pharma Secures USFDA Approval for Glaucoma Treatment, Eyeing $171 Million Market
Gland Pharma has received USFDA approval for Latanoprostene Bunod Ophthalmic Solution, 0.024%, a treatment for glaucoma and ocular hypertension. The product is bioequivalent to Bausch and Lomb's VYZULTA and had U.S. sales of $171 million in the year ending February 2023. As the exclusive First-to-File applicant, Gland Pharma is eligible for 180 days of generic drug exclusivity. This approval marks a significant expansion of the company's presence in the U.S. ophthalmic market.
16Apr 25
ICICI Prudential MF Boosts Stake in Gland Pharma Amid Stock Price Volatility
ICICI Prudential Mutual Fund increased its stake in Gland Pharma to 5.08% by acquiring 400,020 shares on April 11, 2025. This led to a 0.80% rise in Gland Pharma's stock price to ₹1,439.00, despite a 10% decline in April due to concerns over potential U.S. pharmaceutical tariffs. The institutional investment signals confidence in the company's long-term prospects amidst industry challenges.
03Apr 25
Gland Pharma Secures FDA Approval for Acetaminophen Injection, Tapping into $55 Million US Market
Gland Pharma received USFDA approval for Acetaminophen Injection (10 mg/mL) in 500mg/50mL and 1000mg/100mL bags. The product is bioequivalent to B. Braun Medical's reference drug. The US market for this injection is valued at $55 million annually. Indicated for pain management in adults and children over 2 years, the product will be launched through a marketing partner.
25Feb 25
Gland Pharma's USFDA Inspection at Visakhapatnam Facility Results in Three Observations
Gland Pharma's Visakhapatnam facility underwent a US FDA inspection from February 19-25, 2025, resulting in three Form 483 observations. The company states these are procedural, not repeated, and unrelated to data integrity. Gland Pharma plans to submit corrective actions within the stipulated timeframe. The company also announced upcoming one-on-one meetings with institutional investors on February 27 and 28, 2025.
Gland Pharma
1,878.00
+44.40
(+2.42%)
1 Year Returns:+3.29%
Industry Peers
Sun Pharmaceutical
1,667.20
(-0.51%)
Divis Laboratories
6,856.50
(+0.69%)
Cipla
1,515.70
(+0.65%)
Torrent Pharmaceuticals
3,416.70
(+0.25%)
Dr Reddys Laboratories
1,276.80
(-0.51%)
Zydus Life Science
1,002.50
(+1.27%)
Mankind Pharma
2,287.00
(-1.41%)
Lupin
1,960.90
(+1.18%)
Abbott
34,665.00
(-2.82%)
Aurobindo Pharma
1,132.50
(-0.20%)